

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.

Demonstrators protest pharmaceutical companies' lobbying outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, D.C. on September 21, 2021. (Photo: Saul Loeb/AFP via Getty Images)
New research published Wednesday shows that since the coronavirus pandemic began more than two years ago, the five largest pharmaceutical companies in the United States have spent nearly $150 million lobbying against Democratic proposals to lower the country's increasingly outlandish drug prices.
" Big Pharma, like many other industries, knows they cannot justify raising prices so high at the same time they boast of excessive profits."
The analysis by the corporate and government watchdog group Accountable.US estimates that Johnson & Johnson, Eli Lilly, Pfizer, AbbVie, and Merck poured a combined $147.3 million into lobbying Congress since 2020.
"Meanwhile, major pharmaceutical CEOs raked in over $292.6 million" as "their companies saw skyrocketing profits," the report notes.
"Big Pharma, like many other industries, knows they cannot justify raising prices so high at the same time they boast of excessive profits, generous CEO bonuses, and huge shareholder payouts," said Accountable.US spokesperson Liz Zelnick. "That is why the big drug companies spend so massively lobbying to keep the market rigged in their favor and seniors at their mercy, including many literally choosing between food and medicine."
"It is time the conservatives in Congress who complain constantly about inflation finally do something constructive about it--and there's no better place to start than allowing Medicare to finally negotiate lower drug prices," Zelnick added. "What really matters most to these lawmakers: bringing down costs for seniors, or looking out for the bottom line of their big drug company donors?"
The fresh research on Big Pharma's influence-peddling comes as Senate Democrats are working toward a compromise proposal that would allow Medicare to negotiate the prices of a small subset of prescription medicines directly with drug firms that have been pushing up costs with abandon for years.
In 2021, according to one recent study, nearly 18 million U.S. adults couldn't afford at least one medication prescribed by their doctor.
Related Content

In its current form, the new Democratic plan would cap Medicare Part D enrollees' out-of-pocket prescription drug costs at $2,000 annually, penalize pharmaceutical companies that raise prices at a faster rate than inflation, and require Medicare to negotiate the prices of a limited number of drugs.
The Congressional Budget Office projects the measure would save the U.S.--which spends far more on prescription drugs than other wealthy nations--$290 billion over 10 years.
Unsurprisingly, Pharmaceutical Research and Manufacturers of America (PhRMA)--the drug industry's trade group--has denounced the proposal, decrying its "sweeping government price-setting policies."
Last year, Big Pharma spent heavily to weaken an earlier Democratic drug pricing plan that was ultimately scrapped thanks in large part to Sen. Joe Manchin (D-W.Va.).
While it's despised by the pharmaceutical industry--whose lobbyists on Capitol Hill outnumber members of Congress--the idea of allowing Medicare to directly negotiate drug prices is broadly popular with the U.S. public, garnering more than 80% support across party lines in some polling.
"Giving Medicare the power to negotiate lower drug prices is popular, necessary, and will save lives," the progressive advocacy group Social Security Works said Wednesday. "Now it's time for Democrats in Congress to deliver for us."
This country and this world are at a monumental crossroads. US voters have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. If you share our vision, please contribute whatever you can to sustain our work. |
New research published Wednesday shows that since the coronavirus pandemic began more than two years ago, the five largest pharmaceutical companies in the United States have spent nearly $150 million lobbying against Democratic proposals to lower the country's increasingly outlandish drug prices.
" Big Pharma, like many other industries, knows they cannot justify raising prices so high at the same time they boast of excessive profits."
The analysis by the corporate and government watchdog group Accountable.US estimates that Johnson & Johnson, Eli Lilly, Pfizer, AbbVie, and Merck poured a combined $147.3 million into lobbying Congress since 2020.
"Meanwhile, major pharmaceutical CEOs raked in over $292.6 million" as "their companies saw skyrocketing profits," the report notes.
"Big Pharma, like many other industries, knows they cannot justify raising prices so high at the same time they boast of excessive profits, generous CEO bonuses, and huge shareholder payouts," said Accountable.US spokesperson Liz Zelnick. "That is why the big drug companies spend so massively lobbying to keep the market rigged in their favor and seniors at their mercy, including many literally choosing between food and medicine."
"It is time the conservatives in Congress who complain constantly about inflation finally do something constructive about it--and there's no better place to start than allowing Medicare to finally negotiate lower drug prices," Zelnick added. "What really matters most to these lawmakers: bringing down costs for seniors, or looking out for the bottom line of their big drug company donors?"
The fresh research on Big Pharma's influence-peddling comes as Senate Democrats are working toward a compromise proposal that would allow Medicare to negotiate the prices of a small subset of prescription medicines directly with drug firms that have been pushing up costs with abandon for years.
In 2021, according to one recent study, nearly 18 million U.S. adults couldn't afford at least one medication prescribed by their doctor.
Related Content

In its current form, the new Democratic plan would cap Medicare Part D enrollees' out-of-pocket prescription drug costs at $2,000 annually, penalize pharmaceutical companies that raise prices at a faster rate than inflation, and require Medicare to negotiate the prices of a limited number of drugs.
The Congressional Budget Office projects the measure would save the U.S.--which spends far more on prescription drugs than other wealthy nations--$290 billion over 10 years.
Unsurprisingly, Pharmaceutical Research and Manufacturers of America (PhRMA)--the drug industry's trade group--has denounced the proposal, decrying its "sweeping government price-setting policies."
Last year, Big Pharma spent heavily to weaken an earlier Democratic drug pricing plan that was ultimately scrapped thanks in large part to Sen. Joe Manchin (D-W.Va.).
While it's despised by the pharmaceutical industry--whose lobbyists on Capitol Hill outnumber members of Congress--the idea of allowing Medicare to directly negotiate drug prices is broadly popular with the U.S. public, garnering more than 80% support across party lines in some polling.
"Giving Medicare the power to negotiate lower drug prices is popular, necessary, and will save lives," the progressive advocacy group Social Security Works said Wednesday. "Now it's time for Democrats in Congress to deliver for us."
New research published Wednesday shows that since the coronavirus pandemic began more than two years ago, the five largest pharmaceutical companies in the United States have spent nearly $150 million lobbying against Democratic proposals to lower the country's increasingly outlandish drug prices.
" Big Pharma, like many other industries, knows they cannot justify raising prices so high at the same time they boast of excessive profits."
The analysis by the corporate and government watchdog group Accountable.US estimates that Johnson & Johnson, Eli Lilly, Pfizer, AbbVie, and Merck poured a combined $147.3 million into lobbying Congress since 2020.
"Meanwhile, major pharmaceutical CEOs raked in over $292.6 million" as "their companies saw skyrocketing profits," the report notes.
"Big Pharma, like many other industries, knows they cannot justify raising prices so high at the same time they boast of excessive profits, generous CEO bonuses, and huge shareholder payouts," said Accountable.US spokesperson Liz Zelnick. "That is why the big drug companies spend so massively lobbying to keep the market rigged in their favor and seniors at their mercy, including many literally choosing between food and medicine."
"It is time the conservatives in Congress who complain constantly about inflation finally do something constructive about it--and there's no better place to start than allowing Medicare to finally negotiate lower drug prices," Zelnick added. "What really matters most to these lawmakers: bringing down costs for seniors, or looking out for the bottom line of their big drug company donors?"
The fresh research on Big Pharma's influence-peddling comes as Senate Democrats are working toward a compromise proposal that would allow Medicare to negotiate the prices of a small subset of prescription medicines directly with drug firms that have been pushing up costs with abandon for years.
In 2021, according to one recent study, nearly 18 million U.S. adults couldn't afford at least one medication prescribed by their doctor.
Related Content

In its current form, the new Democratic plan would cap Medicare Part D enrollees' out-of-pocket prescription drug costs at $2,000 annually, penalize pharmaceutical companies that raise prices at a faster rate than inflation, and require Medicare to negotiate the prices of a limited number of drugs.
The Congressional Budget Office projects the measure would save the U.S.--which spends far more on prescription drugs than other wealthy nations--$290 billion over 10 years.
Unsurprisingly, Pharmaceutical Research and Manufacturers of America (PhRMA)--the drug industry's trade group--has denounced the proposal, decrying its "sweeping government price-setting policies."
Last year, Big Pharma spent heavily to weaken an earlier Democratic drug pricing plan that was ultimately scrapped thanks in large part to Sen. Joe Manchin (D-W.Va.).
While it's despised by the pharmaceutical industry--whose lobbyists on Capitol Hill outnumber members of Congress--the idea of allowing Medicare to directly negotiate drug prices is broadly popular with the U.S. public, garnering more than 80% support across party lines in some polling.
"Giving Medicare the power to negotiate lower drug prices is popular, necessary, and will save lives," the progressive advocacy group Social Security Works said Wednesday. "Now it's time for Democrats in Congress to deliver for us."